# Pharmacodynamic Evaluation of Intranasal Nalmefene

> **NCT04828005** · PHASE1 · COMPLETED · sponsor: **Opiant Pharmaceuticals Inc** · enrollment: 84 (actual)

## Conditions studied

- Pharmacodynamic

## Interventions

- **DRUG:** Nalmefene hydrochloride
- **DRUG:** Naloxone hydrochloride

## Key facts

- **NCT ID:** NCT04828005
- **Lead sponsor:** Opiant Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-30
- **Primary completion:** 2022-03-14
- **Final completion:** 2022-03-14
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04828005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04828005, "Pharmacodynamic Evaluation of Intranasal Nalmefene". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04828005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*